Andrew R. Allen, BM, BCh, MA, MRCP, PhD, Executive Vice President of Clinical and Pre-Clinical Development, Chief Medical Officer, Co-Founder, Clovis Oncology, discusses how patients are selected for treatment with CO-1686.
Andrew R. Allen, BM, BCh, MA, MRCP, PhD
Articles by Andrew R. Allen, BM, BCh, MA, MRCP, PhD
Latest Updated Articles
Selecting Patients for Treatment with CO-1686September 2nd 2014